nodes	percent_of_prediction	percent_of_DWPC	metapath
Valsartan—CYP2C9—Diclofenamide—glaucoma	0.0963	0.354	CbGbCtD
Valsartan—CYP2C9—Dorzolamide—glaucoma	0.093	0.342	CbGbCtD
Valsartan—CYP2C9—Methazolamide—glaucoma	0.0829	0.305	CbGbCtD
Valsartan—AGTR1—ACE Inhibitor Pathway—MAS1—glaucoma	0.0109	0.129	CbGpPWpGaD
Valsartan—AGTR1—ACE Inhibitor Pathway—ACE2—glaucoma	0.00829	0.098	CbGpPWpGaD
Valsartan—CYP2C9—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1B1—glaucoma	0.00185	0.0219	CbGpPWpGaD
Valsartan—AGTR1—ACE Inhibitor Pathway—NOS3—glaucoma	0.00182	0.0216	CbGpPWpGaD
Valsartan—CYP2C9—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1B1—glaucoma	0.00169	0.02	CbGpPWpGaD
Valsartan—AGTR1—G alpha (q) signalling events—OPN4—glaucoma	0.00147	0.0174	CbGpPWpGaD
Valsartan—ALB—HDL-mediated lipid transport—ABCA1—glaucoma	0.00137	0.0162	CbGpPWpGaD
Valsartan—AGTR1—G alpha (q) signalling events—PTGFR—glaucoma	0.00132	0.0156	CbGpPWpGaD
Valsartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—OPN4—glaucoma	0.00131	0.0155	CbGpPWpGaD
Valsartan—AGTR1—GPCRs, Class A Rhodopsin-like—MAS1—glaucoma	0.00124	0.0147	CbGpPWpGaD
Valsartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—PTGFR—glaucoma	0.00118	0.014	CbGpPWpGaD
Valsartan—AGTR1—GPCRs, Class A Rhodopsin-like—OPN4—glaucoma	0.00114	0.0134	CbGpPWpGaD
Valsartan—SLCO1B3—SLC-mediated transmembrane transport—SLC4A4—glaucoma	0.00108	0.0127	CbGpPWpGaD
Valsartan—AGTR1—GPCRs, Class A Rhodopsin-like—PTGFR—glaucoma	0.00102	0.0121	CbGpPWpGaD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—OPN4—glaucoma	0.000973	0.0115	CbGpPWpGaD
Valsartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—FN1—glaucoma	0.000968	0.0115	CbGpPWpGaD
Valsartan—ALB—HDL-mediated lipid transport—APOE—glaucoma	0.000901	0.0107	CbGpPWpGaD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—PTGFR—glaucoma	0.000876	0.0104	CbGpPWpGaD
Valsartan—AGTR1—Allograft Rejection—IL1A—glaucoma	0.000871	0.0103	CbGpPWpGaD
Valsartan—CYP2C9—Tamoxifen metabolism—CYP1B1—glaucoma	0.000857	0.0101	CbGpPWpGaD
Valsartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—MMP2—glaucoma	0.000821	0.00971	CbGpPWpGaD
Valsartan—SLCO1B3—Transmembrane transport of small molecules—PEX19—glaucoma	0.00081	0.00957	CbGpPWpGaD
Valsartan—ALB—Lipoprotein metabolism—ABCA1—glaucoma	0.000787	0.00931	CbGpPWpGaD
Valsartan—Muscle spasms—Clonidine—glaucoma	0.000785	0.00122	CcSEcCtD
Valsartan—Dyspnoea—Travoprost—glaucoma	0.000784	0.00122	CcSEcCtD
Valsartan—Hypotension—Pilocarpine—glaucoma	0.00078	0.00121	CcSEcCtD
Valsartan—Paraesthesia—Brinzolamide—glaucoma	0.00078	0.00121	CcSEcCtD
Valsartan—Dyspepsia—Dorzolamide—glaucoma	0.000778	0.00121	CcSEcCtD
Valsartan—AGTR1—Allograft Rejection—FAS—glaucoma	0.000776	0.00918	CbGpPWpGaD
Valsartan—Upper respiratory tract infection—Timolol—glaucoma	0.000775	0.0012	CcSEcCtD
Valsartan—Dyspnoea—Brinzolamide—glaucoma	0.000774	0.0012	CcSEcCtD
Valsartan—Dyspepsia—Travoprost—glaucoma	0.000774	0.0012	CcSEcCtD
Valsartan—Asthenia—Apraclonidine—glaucoma	0.000773	0.0012	CcSEcCtD
Valsartan—Somnolence—Brinzolamide—glaucoma	0.000772	0.0012	CcSEcCtD
Valsartan—Vision blurred—Clonidine—glaucoma	0.00077	0.0012	CcSEcCtD
Valsartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—NOS3—glaucoma	0.000769	0.0091	CbGpPWpGaD
Valsartan—Decreased appetite—Dorzolamide—glaucoma	0.000768	0.00119	CcSEcCtD
Valsartan—Erectile dysfunction—Timolol—glaucoma	0.000768	0.00119	CcSEcCtD
Valsartan—Urticaria—Acetazolamide—glaucoma	0.000766	0.00119	CcSEcCtD
Valsartan—AGTR1—Allograft Rejection—C3—glaucoma	0.000765	0.00905	CbGpPWpGaD
Valsartan—Dyspepsia—Brinzolamide—glaucoma	0.000764	0.00119	CcSEcCtD
Valsartan—Pruritus—Apraclonidine—glaucoma	0.000762	0.00119	CcSEcCtD
Valsartan—Fatigue—Dorzolamide—glaucoma	0.000762	0.00118	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Pilocarpine—glaucoma	0.00076	0.00118	CcSEcCtD
Valsartan—Gastrointestinal disorder—Travoprost—glaucoma	0.000759	0.00118	CcSEcCtD
Valsartan—Fatigue—Travoprost—glaucoma	0.000758	0.00118	CcSEcCtD
Valsartan—Cardiac disorder—Betaxolol—glaucoma	0.000758	0.00118	CcSEcCtD
Valsartan—Insomnia—Pilocarpine—glaucoma	0.000755	0.00117	CcSEcCtD
Valsartan—Decreased appetite—Brinzolamide—glaucoma	0.000755	0.00117	CcSEcCtD
Valsartan—Constipation—Travoprost—glaucoma	0.000752	0.00117	CcSEcCtD
Valsartan—Gastrointestinal disorder—Brinzolamide—glaucoma	0.00075	0.00117	CcSEcCtD
Valsartan—Paraesthesia—Pilocarpine—glaucoma	0.000749	0.00117	CcSEcCtD
Valsartan—Asthenia—Bimatoprost—glaucoma	0.000749	0.00117	CcSEcCtD
Valsartan—Fatigue—Brinzolamide—glaucoma	0.000749	0.00116	CcSEcCtD
Valsartan—Angioedema—Clonidine—glaucoma	0.000746	0.00116	CcSEcCtD
Valsartan—Dyspnoea—Pilocarpine—glaucoma	0.000744	0.00116	CcSEcCtD
Valsartan—Somnolence—Pilocarpine—glaucoma	0.000742	0.00115	CcSEcCtD
Valsartan—Angiopathy—Betaxolol—glaucoma	0.000741	0.00115	CcSEcCtD
Valsartan—AGTR1—GPCR ligand binding—OPN4—glaucoma	0.000741	0.00876	CbGpPWpGaD
Valsartan—Pruritus—Bimatoprost—glaucoma	0.000739	0.00115	CcSEcCtD
Valsartan—Immune system disorder—Betaxolol—glaucoma	0.000738	0.00115	CcSEcCtD
Valsartan—Diarrhoea—Apraclonidine—glaucoma	0.000737	0.00115	CcSEcCtD
Valsartan—Mediastinal disorder—Betaxolol—glaucoma	0.000736	0.00114	CcSEcCtD
Valsartan—Dyspepsia—Pilocarpine—glaucoma	0.000735	0.00114	CcSEcCtD
Valsartan—Syncope—Clonidine—glaucoma	0.000732	0.00114	CcSEcCtD
Valsartan—Decreased appetite—Pilocarpine—glaucoma	0.000726	0.00113	CcSEcCtD
Valsartan—SLCO1B1—SLC-mediated transmembrane transport—SLC4A4—glaucoma	0.000723	0.00855	CbGpPWpGaD
Valsartan—Gastrointestinal pain—Dorzolamide—glaucoma	0.000722	0.00112	CcSEcCtD
Valsartan—Alopecia—Betaxolol—glaucoma	0.000722	0.00112	CcSEcCtD
Valsartan—Palpitations—Clonidine—glaucoma	0.000722	0.00112	CcSEcCtD
Valsartan—Gastrointestinal disorder—Pilocarpine—glaucoma	0.000721	0.00112	CcSEcCtD
Valsartan—Gastrointestinal pain—Travoprost—glaucoma	0.000719	0.00112	CcSEcCtD
Valsartan—SLCO1B3—SLC-mediated transmembrane transport—SLC6A13—glaucoma	0.000718	0.00849	CbGpPWpGaD
Valsartan—Loss of consciousness—Clonidine—glaucoma	0.000718	0.00112	CcSEcCtD
Valsartan—Mental disorder—Betaxolol—glaucoma	0.000716	0.00111	CcSEcCtD
Valsartan—Constipation—Pilocarpine—glaucoma	0.000714	0.00111	CcSEcCtD
Valsartan—Cough—Clonidine—glaucoma	0.000713	0.00111	CcSEcCtD
Valsartan—Dizziness—Apraclonidine—glaucoma	0.000712	0.00111	CcSEcCtD
Valsartan—Malnutrition—Betaxolol—glaucoma	0.000711	0.00111	CcSEcCtD
Valsartan—Urticaria—Dorzolamide—glaucoma	0.000702	0.00109	CcSEcCtD
Valsartan—Epistaxis—Timolol—glaucoma	0.000701	0.00109	CcSEcCtD
Valsartan—Abdominal pain—Dorzolamide—glaucoma	0.000698	0.00109	CcSEcCtD
Valsartan—Sinusitis—Timolol—glaucoma	0.000697	0.00108	CcSEcCtD
Valsartan—Dysgeusia—Betaxolol—glaucoma	0.000696	0.00108	CcSEcCtD
Valsartan—Chest pain—Clonidine—glaucoma	0.000695	0.00108	CcSEcCtD
Valsartan—Arthralgia—Clonidine—glaucoma	0.000695	0.00108	CcSEcCtD
Valsartan—Abdominal pain—Travoprost—glaucoma	0.000695	0.00108	CcSEcCtD
Valsartan—Anxiety—Clonidine—glaucoma	0.000693	0.00108	CcSEcCtD
Valsartan—Asthenia—Acetazolamide—glaucoma	0.000691	0.00108	CcSEcCtD
Valsartan—Dizziness—Bimatoprost—glaucoma	0.000691	0.00107	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Clonidine—glaucoma	0.000691	0.00107	CcSEcCtD
Valsartan—Urticaria—Brinzolamide—glaucoma	0.00069	0.00107	CcSEcCtD
Valsartan—Vomiting—Apraclonidine—glaucoma	0.000685	0.00107	CcSEcCtD
Valsartan—Muscle spasms—Betaxolol—glaucoma	0.000684	0.00106	CcSEcCtD
Valsartan—Gastrointestinal pain—Pilocarpine—glaucoma	0.000683	0.00106	CcSEcCtD
Valsartan—Hypersensitivity—Brimonidine—glaucoma	0.000681	0.00106	CcSEcCtD
Valsartan—Dry mouth—Clonidine—glaucoma	0.00068	0.00106	CcSEcCtD
Valsartan—Dermatitis—Apraclonidine—glaucoma	0.000679	0.00106	CcSEcCtD
Valsartan—Headache—Apraclonidine—glaucoma	0.000675	0.00105	CcSEcCtD
Valsartan—Vision blurred—Betaxolol—glaucoma	0.00067	0.00104	CcSEcCtD
Valsartan—Rhinitis—Timolol—glaucoma	0.000669	0.00104	CcSEcCtD
Valsartan—AGTR1—GPCR ligand binding—PTGFR—glaucoma	0.000667	0.00788	CbGpPWpGaD
Valsartan—Oedema—Clonidine—glaucoma	0.000667	0.00104	CcSEcCtD
Valsartan—Asthenia—Brimonidine—glaucoma	0.000664	0.00103	CcSEcCtD
Valsartan—Infection—Clonidine—glaucoma	0.000662	0.00103	CcSEcCtD
Valsartan—Abdominal pain—Pilocarpine—glaucoma	0.00066	0.00103	CcSEcCtD
Valsartan—Diarrhoea—Acetazolamide—glaucoma	0.000659	0.00103	CcSEcCtD
Valsartan—Rash—Bimatoprost—glaucoma	0.000659	0.00102	CcSEcCtD
Valsartan—Dermatitis—Bimatoprost—glaucoma	0.000658	0.00102	CcSEcCtD
Valsartan—Shock—Clonidine—glaucoma	0.000656	0.00102	CcSEcCtD
Valsartan—Connective tissue disorder—Timolol—glaucoma	0.000656	0.00102	CcSEcCtD
Valsartan—Pruritus—Brimonidine—glaucoma	0.000654	0.00102	CcSEcCtD
Valsartan—Headache—Bimatoprost—glaucoma	0.000654	0.00102	CcSEcCtD
Valsartan—Nervous system disorder—Clonidine—glaucoma	0.000654	0.00102	CcSEcCtD
Valsartan—Thrombocytopenia—Clonidine—glaucoma	0.000653	0.00101	CcSEcCtD
Valsartan—Hypersensitivity—Dorzolamide—glaucoma	0.000651	0.00101	CcSEcCtD
Valsartan—Hypersensitivity—Travoprost—glaucoma	0.000648	0.00101	CcSEcCtD
Valsartan—Skin disorder—Clonidine—glaucoma	0.000647	0.00101	CcSEcCtD
Valsartan—Nausea—Apraclonidine—glaucoma	0.00064	0.000995	CcSEcCtD
Valsartan—Hypersensitivity—Brinzolamide—glaucoma	0.00064	0.000995	CcSEcCtD
Valsartan—Vertigo—Betaxolol—glaucoma	0.000639	0.000993	CcSEcCtD
Valsartan—Syncope—Betaxolol—glaucoma	0.000638	0.000991	CcSEcCtD
Valsartan—Dizziness—Acetazolamide—glaucoma	0.000637	0.000991	CcSEcCtD
Valsartan—Anorexia—Clonidine—glaucoma	0.000635	0.000988	CcSEcCtD
Valsartan—Asthenia—Dorzolamide—glaucoma	0.000634	0.000985	CcSEcCtD
Valsartan—Asthenia—Travoprost—glaucoma	0.000631	0.000981	CcSEcCtD
Valsartan—Palpitations—Betaxolol—glaucoma	0.000628	0.000977	CcSEcCtD
Valsartan—Pruritus—Dorzolamide—glaucoma	0.000625	0.000972	CcSEcCtD
Valsartan—Loss of consciousness—Betaxolol—glaucoma	0.000625	0.000972	CcSEcCtD
Valsartan—Asthenia—Brinzolamide—glaucoma	0.000623	0.000969	CcSEcCtD
Valsartan—Hypotension—Clonidine—glaucoma	0.000623	0.000968	CcSEcCtD
Valsartan—Pruritus—Travoprost—glaucoma	0.000622	0.000968	CcSEcCtD
Valsartan—Cough—Betaxolol—glaucoma	0.00062	0.000965	CcSEcCtD
Valsartan—Nausea—Bimatoprost—glaucoma	0.00062	0.000965	CcSEcCtD
Valsartan—Cardiac disorder—Timolol—glaucoma	0.000619	0.000963	CcSEcCtD
Valsartan—Hypersensitivity—Pilocarpine—glaucoma	0.000615	0.000956	CcSEcCtD
Valsartan—Pruritus—Brinzolamide—glaucoma	0.000614	0.000955	CcSEcCtD
Valsartan—Vomiting—Acetazolamide—glaucoma	0.000613	0.000953	CcSEcCtD
Valsartan—Dizziness—Brimonidine—glaucoma	0.000612	0.000951	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Clonidine—glaucoma	0.000607	0.000944	CcSEcCtD
Valsartan—Angiopathy—Timolol—glaucoma	0.000605	0.000941	CcSEcCtD
Valsartan—Arthralgia—Betaxolol—glaucoma	0.000605	0.000941	CcSEcCtD
Valsartan—Myalgia—Betaxolol—glaucoma	0.000605	0.000941	CcSEcCtD
Valsartan—Chest pain—Betaxolol—glaucoma	0.000605	0.000941	CcSEcCtD
Valsartan—Diarrhoea—Dorzolamide—glaucoma	0.000604	0.00094	CcSEcCtD
Valsartan—Headache—Acetazolamide—glaucoma	0.000604	0.000939	CcSEcCtD
Valsartan—Anxiety—Betaxolol—glaucoma	0.000603	0.000938	CcSEcCtD
Valsartan—Insomnia—Clonidine—glaucoma	0.000603	0.000937	CcSEcCtD
Valsartan—Immune system disorder—Timolol—glaucoma	0.000603	0.000937	CcSEcCtD
Valsartan—Diarrhoea—Travoprost—glaucoma	0.000602	0.000936	CcSEcCtD
Valsartan—Mediastinal disorder—Timolol—glaucoma	0.000601	0.000935	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Betaxolol—glaucoma	0.000601	0.000935	CcSEcCtD
Valsartan—Asthenia—Pilocarpine—glaucoma	0.000599	0.000931	CcSEcCtD
Valsartan—Paraesthesia—Clonidine—glaucoma	0.000599	0.000931	CcSEcCtD
Valsartan—Dyspnoea—Clonidine—glaucoma	0.000594	0.000924	CcSEcCtD
Valsartan—Diarrhoea—Brinzolamide—glaucoma	0.000594	0.000924	CcSEcCtD
Valsartan—Somnolence—Clonidine—glaucoma	0.000593	0.000921	CcSEcCtD
Valsartan—Dry mouth—Betaxolol—glaucoma	0.000592	0.000921	CcSEcCtD
Valsartan—Pruritus—Pilocarpine—glaucoma	0.000591	0.000918	CcSEcCtD
Valsartan—Alopecia—Timolol—glaucoma	0.00059	0.000917	CcSEcCtD
Valsartan—Mental disorder—Timolol—glaucoma	0.000585	0.000909	CcSEcCtD
Valsartan—Dizziness—Dorzolamide—glaucoma	0.000584	0.000908	CcSEcCtD
Valsartan—Rash—Brimonidine—glaucoma	0.000583	0.000907	CcSEcCtD
Valsartan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCA1—glaucoma	0.000583	0.00689	CbGpPWpGaD
Valsartan—Dermatitis—Brimonidine—glaucoma	0.000583	0.000906	CcSEcCtD
Valsartan—Dizziness—Travoprost—glaucoma	0.000582	0.000904	CcSEcCtD
Valsartan—Malnutrition—Timolol—glaucoma	0.000581	0.000903	CcSEcCtD
Valsartan—Oedema—Betaxolol—glaucoma	0.00058	0.000902	CcSEcCtD
Valsartan—Headache—Brimonidine—glaucoma	0.000579	0.000901	CcSEcCtD
Valsartan—Decreased appetite—Clonidine—glaucoma	0.000579	0.000901	CcSEcCtD
Valsartan—Infection—Betaxolol—glaucoma	0.000576	0.000896	CcSEcCtD
Valsartan—Gastrointestinal disorder—Clonidine—glaucoma	0.000575	0.000895	CcSEcCtD
Valsartan—Fatigue—Clonidine—glaucoma	0.000575	0.000894	CcSEcCtD
Valsartan—Dizziness—Brinzolamide—glaucoma	0.000574	0.000893	CcSEcCtD
Valsartan—Nausea—Acetazolamide—glaucoma	0.000572	0.00089	CcSEcCtD
Valsartan—Diarrhoea—Pilocarpine—glaucoma	0.000571	0.000888	CcSEcCtD
Valsartan—Shock—Betaxolol—glaucoma	0.000571	0.000888	CcSEcCtD
Valsartan—Constipation—Clonidine—glaucoma	0.00057	0.000886	CcSEcCtD
Valsartan—Nervous system disorder—Betaxolol—glaucoma	0.000569	0.000885	CcSEcCtD
Valsartan—Dysgeusia—Timolol—glaucoma	0.000569	0.000884	CcSEcCtD
Valsartan—Thrombocytopenia—Betaxolol—glaucoma	0.000568	0.000883	CcSEcCtD
Valsartan—Skin disorder—Betaxolol—glaucoma	0.000564	0.000876	CcSEcCtD
Valsartan—Vomiting—Dorzolamide—glaucoma	0.000562	0.000873	CcSEcCtD
Valsartan—Rash—Dorzolamide—glaucoma	0.000557	0.000866	CcSEcCtD
Valsartan—Dermatitis—Dorzolamide—glaucoma	0.000556	0.000865	CcSEcCtD
Valsartan—Rash—Travoprost—glaucoma	0.000555	0.000862	CcSEcCtD
Valsartan—Dermatitis—Travoprost—glaucoma	0.000554	0.000861	CcSEcCtD
Valsartan—Headache—Dorzolamide—glaucoma	0.000553	0.00086	CcSEcCtD
Valsartan—Anorexia—Betaxolol—glaucoma	0.000553	0.00086	CcSEcCtD
Valsartan—Vomiting—Brinzolamide—glaucoma	0.000552	0.000859	CcSEcCtD
Valsartan—Dizziness—Pilocarpine—glaucoma	0.000552	0.000858	CcSEcCtD
Valsartan—Headache—Travoprost—glaucoma	0.000551	0.000857	CcSEcCtD
Valsartan—Nausea—Brimonidine—glaucoma	0.000549	0.000854	CcSEcCtD
Valsartan—Rash—Brinzolamide—glaucoma	0.000548	0.000851	CcSEcCtD
Valsartan—Vision blurred—Timolol—glaucoma	0.000547	0.000851	CcSEcCtD
Valsartan—Dermatitis—Brinzolamide—glaucoma	0.000547	0.000851	CcSEcCtD
Valsartan—SLCO1B3—Transmembrane transport of small molecules—SLC4A4—glaucoma	0.000547	0.00647	CbGpPWpGaD
Valsartan—Gastrointestinal pain—Clonidine—glaucoma	0.000545	0.000847	CcSEcCtD
Valsartan—Headache—Brinzolamide—glaucoma	0.000544	0.000846	CcSEcCtD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—PEX19—glaucoma	0.000544	0.00643	CbGpPWpGaD
Valsartan—Hypotension—Betaxolol—glaucoma	0.000542	0.000843	CcSEcCtD
Valsartan—ALB—Selenium Micronutrient Network—TXN—glaucoma	0.000539	0.00637	CbGpPWpGaD
Valsartan—Angioedema—Timolol—glaucoma	0.000531	0.000825	CcSEcCtD
Valsartan—Vomiting—Pilocarpine—glaucoma	0.000531	0.000825	CcSEcCtD
Valsartan—Urticaria—Clonidine—glaucoma	0.00053	0.000823	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Betaxolol—glaucoma	0.000529	0.000822	CcSEcCtD
Valsartan—Abdominal pain—Clonidine—glaucoma	0.000527	0.000819	CcSEcCtD
Valsartan—Rash—Pilocarpine—glaucoma	0.000526	0.000818	CcSEcCtD
Valsartan—Dermatitis—Pilocarpine—glaucoma	0.000526	0.000818	CcSEcCtD
Valsartan—SLCO1B3—SLC-mediated transmembrane transport—SLC6A1—glaucoma	0.000526	0.00621	CbGpPWpGaD
Valsartan—Insomnia—Betaxolol—glaucoma	0.000525	0.000816	CcSEcCtD
Valsartan—Nausea—Dorzolamide—glaucoma	0.000525	0.000816	CcSEcCtD
Valsartan—ALB—Lipid and lipoprotein metabolism—ABCA1—glaucoma	0.000523	0.00618	CbGpPWpGaD
Valsartan—Headache—Pilocarpine—glaucoma	0.000523	0.000813	CcSEcCtD
Valsartan—Nausea—Travoprost—glaucoma	0.000522	0.000812	CcSEcCtD
Valsartan—Vertigo—Timolol—glaucoma	0.000522	0.000811	CcSEcCtD
Valsartan—Paraesthesia—Betaxolol—glaucoma	0.000521	0.00081	CcSEcCtD
Valsartan—Syncope—Timolol—glaucoma	0.000521	0.00081	CcSEcCtD
Valsartan—ALB—Lipoprotein metabolism—APOE—glaucoma	0.000518	0.00612	CbGpPWpGaD
Valsartan—Dyspnoea—Betaxolol—glaucoma	0.000517	0.000804	CcSEcCtD
Valsartan—Nausea—Brinzolamide—glaucoma	0.000516	0.000802	CcSEcCtD
Valsartan—ALB—Vitamin B12 Metabolism—ABCA1—glaucoma	0.000515	0.00609	CbGpPWpGaD
Valsartan—Palpitations—Timolol—glaucoma	0.000513	0.000798	CcSEcCtD
Valsartan—Dyspepsia—Betaxolol—glaucoma	0.000511	0.000794	CcSEcCtD
Valsartan—Loss of consciousness—Timolol—glaucoma	0.000511	0.000794	CcSEcCtD
Valsartan—Cough—Timolol—glaucoma	0.000507	0.000788	CcSEcCtD
Valsartan—Decreased appetite—Betaxolol—glaucoma	0.000504	0.000784	CcSEcCtD
Valsartan—Gastrointestinal disorder—Betaxolol—glaucoma	0.000501	0.000779	CcSEcCtD
Valsartan—Fatigue—Betaxolol—glaucoma	0.0005	0.000778	CcSEcCtD
Valsartan—Constipation—Betaxolol—glaucoma	0.000496	0.000772	CcSEcCtD
Valsartan—Nausea—Pilocarpine—glaucoma	0.000496	0.000771	CcSEcCtD
Valsartan—Myalgia—Timolol—glaucoma	0.000495	0.000769	CcSEcCtD
Valsartan—Arthralgia—Timolol—glaucoma	0.000495	0.000769	CcSEcCtD
Valsartan—Chest pain—Timolol—glaucoma	0.000495	0.000769	CcSEcCtD
Valsartan—Anxiety—Timolol—glaucoma	0.000493	0.000766	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Timolol—glaucoma	0.000491	0.000764	CcSEcCtD
Valsartan—Hypersensitivity—Clonidine—glaucoma	0.000491	0.000764	CcSEcCtD
Valsartan—Dry mouth—Timolol—glaucoma	0.000484	0.000752	CcSEcCtD
Valsartan—SLCO1B1—SLC-mediated transmembrane transport—SLC6A13—glaucoma	0.000482	0.0057	CbGpPWpGaD
Valsartan—Asthenia—Clonidine—glaucoma	0.000478	0.000744	CcSEcCtD
Valsartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—TNF—glaucoma	0.000475	0.00562	CbGpPWpGaD
Valsartan—Oedema—Timolol—glaucoma	0.000474	0.000737	CcSEcCtD
Valsartan—Anaphylactic shock—Timolol—glaucoma	0.000474	0.000737	CcSEcCtD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—CTSA—glaucoma	0.000474	0.0056	CbGpPWpGaD
Valsartan—Pruritus—Clonidine—glaucoma	0.000472	0.000733	CcSEcCtD
Valsartan—Infection—Timolol—glaucoma	0.000471	0.000732	CcSEcCtD
Valsartan—Shock—Timolol—glaucoma	0.000466	0.000725	CcSEcCtD
Valsartan—Nervous system disorder—Timolol—glaucoma	0.000465	0.000723	CcSEcCtD
Valsartan—Urticaria—Betaxolol—glaucoma	0.000461	0.000717	CcSEcCtD
Valsartan—Skin disorder—Timolol—glaucoma	0.00046	0.000716	CcSEcCtD
Valsartan—ALB—Vitamin B12 Metabolism—SOD1—glaucoma	0.000459	0.00542	CbGpPWpGaD
Valsartan—Diarrhoea—Clonidine—glaucoma	0.000456	0.000709	CcSEcCtD
Valsartan—Anorexia—Timolol—glaucoma	0.000452	0.000703	CcSEcCtD
Valsartan—SLCO1B3—Metabolism—NARFL—glaucoma	0.000446	0.00527	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—CA5A—glaucoma	0.000446	0.00527	CbGpPWpGaD
Valsartan—Hypotension—Timolol—glaucoma	0.000443	0.000689	CcSEcCtD
Valsartan—Dizziness—Clonidine—glaucoma	0.000441	0.000685	CcSEcCtD
Valsartan—AGTR1—G alpha (q) signalling events—EDN1—glaucoma	0.00044	0.0052	CbGpPWpGaD
Valsartan—AGTR1—Peptide ligand-binding receptors—EDN1—glaucoma	0.000434	0.00513	CbGpPWpGaD
Valsartan—Musculoskeletal discomfort—Timolol—glaucoma	0.000432	0.000672	CcSEcCtD
Valsartan—Insomnia—Timolol—glaucoma	0.000429	0.000667	CcSEcCtD
Valsartan—ALB—FOXA2 and FOXA3 transcription factor networks—NR3C1—glaucoma	0.000429	0.00507	CbGpPWpGaD
Valsartan—CYP2C9—Arachidonic acid metabolism—CYP1B1—glaucoma	0.000428	0.00506	CbGpPWpGaD
Valsartan—Hypersensitivity—Betaxolol—glaucoma	0.000428	0.000665	CcSEcCtD
Valsartan—Paraesthesia—Timolol—glaucoma	0.000426	0.000662	CcSEcCtD
Valsartan—Vomiting—Clonidine—glaucoma	0.000424	0.000659	CcSEcCtD
Valsartan—Dyspnoea—Timolol—glaucoma	0.000423	0.000657	CcSEcCtD
Valsartan—ALB—Platelet degranulation—TGFB2—glaucoma	0.000422	0.00499	CbGpPWpGaD
Valsartan—Somnolence—Timolol—glaucoma	0.000421	0.000655	CcSEcCtD
Valsartan—Rash—Clonidine—glaucoma	0.00042	0.000653	CcSEcCtD
Valsartan—Dermatitis—Clonidine—glaucoma	0.00042	0.000653	CcSEcCtD
Valsartan—ALB—Folate Metabolism—ABCA1—glaucoma	0.000419	0.00495	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—OPN4—glaucoma	0.000419	0.00495	CbGpPWpGaD
Valsartan—Headache—Clonidine—glaucoma	0.000418	0.000649	CcSEcCtD
Valsartan—Dyspepsia—Timolol—glaucoma	0.000417	0.000649	CcSEcCtD
Valsartan—Asthenia—Betaxolol—glaucoma	0.000416	0.000647	CcSEcCtD
Valsartan—ALB—SLC-mediated transmembrane transport—SLC4A4—glaucoma	0.000413	0.00489	CbGpPWpGaD
Valsartan—Decreased appetite—Timolol—glaucoma	0.000412	0.000641	CcSEcCtD
Valsartan—Pruritus—Betaxolol—glaucoma	0.000411	0.000638	CcSEcCtD
Valsartan—Gastrointestinal disorder—Timolol—glaucoma	0.000409	0.000636	CcSEcCtD
Valsartan—Fatigue—Timolol—glaucoma	0.000409	0.000636	CcSEcCtD
Valsartan—ALB—Binding and Uptake of Ligands by Scavenger Receptors—APOE—glaucoma	0.000403	0.00477	CbGpPWpGaD
Valsartan—ALB—Response to elevated platelet cytosolic Ca2+—TGFB2—glaucoma	0.000402	0.00476	CbGpPWpGaD
Valsartan—Diarrhoea—Betaxolol—glaucoma	0.000397	0.000617	CcSEcCtD
Valsartan—Nausea—Clonidine—glaucoma	0.000396	0.000616	CcSEcCtD
Valsartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—glaucoma	0.000393	0.00465	CbGpPWpGaD
Valsartan—Gastrointestinal pain—Timolol—glaucoma	0.000388	0.000603	CcSEcCtD
Valsartan—AGTR1—Allograft Rejection—VEGFA—glaucoma	0.000384	0.00455	CbGpPWpGaD
Valsartan—Dizziness—Betaxolol—glaucoma	0.000384	0.000597	CcSEcCtD
Valsartan—AGTR1—Signaling by GPCR—OPN4—glaucoma	0.00038	0.00449	CbGpPWpGaD
Valsartan—AGTR1—Peptide ligand-binding receptors—C3—glaucoma	0.000379	0.00448	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—PTGFR—glaucoma	0.000377	0.00446	CbGpPWpGaD
Valsartan—Urticaria—Timolol—glaucoma	0.000377	0.000586	CcSEcCtD
Valsartan—Abdominal pain—Timolol—glaucoma	0.000375	0.000583	CcSEcCtD
Valsartan—ALB—Folate Metabolism—SOD1—glaucoma	0.000373	0.00441	CbGpPWpGaD
Valsartan—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1B1—glaucoma	0.00037	0.00437	CbGpPWpGaD
Valsartan—Vomiting—Betaxolol—glaucoma	0.000369	0.000574	CcSEcCtD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—SLC4A4—glaucoma	0.000367	0.00434	CbGpPWpGaD
Valsartan—Rash—Betaxolol—glaucoma	0.000366	0.000569	CcSEcCtD
Valsartan—Dermatitis—Betaxolol—glaucoma	0.000366	0.000568	CcSEcCtD
Valsartan—CYP2C9—Oxidation by Cytochrome P450—CYP1B1—glaucoma	0.000365	0.00432	CbGpPWpGaD
Valsartan—SLCO1B3—Transmembrane transport of small molecules—SLC6A13—glaucoma	0.000365	0.00431	CbGpPWpGaD
Valsartan—ALB—Vitamin B12 Metabolism—MTHFR—glaucoma	0.000364	0.0043	CbGpPWpGaD
Valsartan—Headache—Betaxolol—glaucoma	0.000364	0.000565	CcSEcCtD
Valsartan—SLCO1B1—SLC-mediated transmembrane transport—SLC6A1—glaucoma	0.000353	0.00418	CbGpPWpGaD
Valsartan—Hypersensitivity—Timolol—glaucoma	0.000349	0.000543	CcSEcCtD
Valsartan—Nausea—Betaxolol—glaucoma	0.000345	0.000536	CcSEcCtD
Valsartan—ALB—Lipid and lipoprotein metabolism—APOE—glaucoma	0.000344	0.00407	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—PTGFR—glaucoma	0.000342	0.00405	CbGpPWpGaD
Valsartan—ALB—Lipid and lipoprotein metabolism—CAV1—glaucoma	0.000341	0.00403	CbGpPWpGaD
Valsartan—Asthenia—Timolol—glaucoma	0.00034	0.000529	CcSEcCtD
Valsartan—ALB—Vitamin B12 Metabolism—APOE—glaucoma	0.000339	0.004	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—SMO—glaucoma	0.000336	0.00398	CbGpPWpGaD
Valsartan—Pruritus—Timolol—glaucoma	0.000335	0.000522	CcSEcCtD
Valsartan—ALB—Selenium Micronutrient Network—ABCA1—glaucoma	0.000333	0.00393	CbGpPWpGaD
Valsartan—AGTR1—Allograft Rejection—TNF—glaucoma	0.000329	0.0039	CbGpPWpGaD
Valsartan—Diarrhoea—Timolol—glaucoma	0.000324	0.000504	CcSEcCtD
Valsartan—AGTR1—Signaling Pathways—LRP12—glaucoma	0.000324	0.00383	CbGpPWpGaD
Valsartan—ALB—Platelet degranulation—SOD1—glaucoma	0.00032	0.00378	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—CTSA—glaucoma	0.000318	0.00376	CbGpPWpGaD
Valsartan—Dizziness—Timolol—glaucoma	0.000313	0.000487	CcSEcCtD
Valsartan—ALB—Transmembrane transport of small molecules—PEX19—glaucoma	0.000311	0.00368	CbGpPWpGaD
Valsartan—ALB—Response to elevated platelet cytosolic Ca2+—SOD1—glaucoma	0.000305	0.00361	CbGpPWpGaD
Valsartan—Vomiting—Timolol—glaucoma	0.000301	0.000469	CcSEcCtD
Valsartan—CYP2C9—Phase 1 - Functionalization of compounds—CYP1B1—glaucoma	0.0003	0.00355	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CA5A—glaucoma	0.0003	0.00354	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—NARFL—glaucoma	0.0003	0.00354	CbGpPWpGaD
Valsartan—Rash—Timolol—glaucoma	0.000299	0.000465	CcSEcCtD
Valsartan—Dermatitis—Timolol—glaucoma	0.000299	0.000464	CcSEcCtD
Valsartan—Headache—Timolol—glaucoma	0.000297	0.000462	CcSEcCtD
Valsartan—ALB—Selenium Micronutrient Network—SOD1—glaucoma	0.000297	0.00351	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—MTHFR—glaucoma	0.000296	0.0035	CbGpPWpGaD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—EDN1—glaucoma	0.000291	0.00344	CbGpPWpGaD
Valsartan—Nausea—Timolol—glaucoma	0.000282	0.000438	CcSEcCtD
Valsartan—ALB—SLC-mediated transmembrane transport—SLC6A13—glaucoma	0.000276	0.00326	CbGpPWpGaD
Valsartan—SLCO1B3—Transmembrane transport of small molecules—SLC6A1—glaucoma	0.000267	0.00316	CbGpPWpGaD
Valsartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—C3—glaucoma	0.000254	0.00301	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—SLC6A13—glaucoma	0.000245	0.0029	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—MTHFR—glaucoma	0.000235	0.00278	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—OPN4—glaucoma	0.000225	0.00265	CbGpPWpGaD
Valsartan—ALB—Platelet degranulation—FN1—glaucoma	0.000223	0.00263	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—EDN1—glaucoma	0.000222	0.00262	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—CA1—glaucoma	0.000218	0.00258	CbGpPWpGaD
Valsartan—ALB—Response to elevated platelet cytosolic Ca2+—FN1—glaucoma	0.000212	0.00251	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—CTSA—glaucoma	0.000211	0.00249	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—SLC4A4—glaucoma	0.00021	0.00248	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—HEYL—glaucoma	0.000209	0.00247	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—PTGFR—glaucoma	0.000202	0.00239	CbGpPWpGaD
Valsartan—ALB—SLC-mediated transmembrane transport—SLC6A1—glaucoma	0.000202	0.00239	CbGpPWpGaD
Valsartan—CYP2C9—Biological oxidations—GSTT1—glaucoma	0.0002	0.00236	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—CA2—glaucoma	0.000199	0.00236	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—ABCA1—glaucoma	0.000195	0.0023	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—CYP1B1—glaucoma	0.000195	0.0023	CbGpPWpGaD
Valsartan—AGTR1—GPCR ligand binding—C3—glaucoma	0.000194	0.00229	CbGpPWpGaD
Valsartan—CYP2C9—Arachidonic acid metabolism—PTGS2—glaucoma	0.000193	0.00228	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—TGFB2—glaucoma	0.000187	0.00221	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—CTSA—glaucoma	0.000182	0.00215	CbGpPWpGaD
Valsartan—SLCO1B1—Transmembrane transport of small molecules—SLC6A1—glaucoma	0.000179	0.00212	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—SMO—glaucoma	0.000173	0.00204	CbGpPWpGaD
Valsartan—ALB—Metabolism—CA5A—glaucoma	0.000171	0.00202	CbGpPWpGaD
Valsartan—ALB—Metabolism—NARFL—glaucoma	0.000171	0.00202	CbGpPWpGaD
Valsartan—CYP2C9—Biological oxidations—CYP1B1—glaucoma	0.000159	0.00188	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—RPTOR—glaucoma	0.000158	0.00187	CbGpPWpGaD
Valsartan—CYP2C9—Metapathway biotransformation—CYP1B1—glaucoma	0.000157	0.00186	CbGpPWpGaD
Valsartan—ALB—Vitamin B12 Metabolism—TNF—glaucoma	0.000157	0.00185	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—NCK2—glaucoma	0.000153	0.00181	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—PTGS2—glaucoma	0.00015	0.00177	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—CTSA—glaucoma	0.000149	0.00176	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CA1—glaucoma	0.000146	0.00173	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—SOD1—glaucoma	0.000142	0.00168	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CTSA—glaucoma	0.000142	0.00168	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—TXN—glaucoma	0.00014	0.00166	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—NARFL—glaucoma	0.00014	0.00166	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CA5A—glaucoma	0.00014	0.00166	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—SLC6A13—glaucoma	0.00014	0.00166	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CA2—glaucoma	0.000134	0.00158	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—CYP1B1—glaucoma	0.000131	0.00155	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—ABCA1—glaucoma	0.000131	0.00155	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—HDAC9—glaucoma	0.00013	0.00154	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—APOE—glaucoma	0.000128	0.00151	CbGpPWpGaD
Valsartan—ALB—Platelet degranulation—VEGFA—glaucoma	0.000127	0.00151	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—TNF—glaucoma	0.000127	0.00151	CbGpPWpGaD
Valsartan—CYP2C9—Biological oxidations—GSTM1—glaucoma	0.000127	0.00151	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—CAV1—glaucoma	0.000127	0.0015	CbGpPWpGaD
Valsartan—CYP2C9—Metapathway biotransformation—GSTM1—glaucoma	0.000126	0.00149	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—EDN1—glaucoma	0.000125	0.00148	CbGpPWpGaD
Valsartan—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—glaucoma	0.000121	0.00144	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—EDN1—glaucoma	0.000114	0.00135	CbGpPWpGaD
Valsartan—ALB—Folate Metabolism—TP53—glaucoma	0.000112	0.00133	CbGpPWpGaD
Valsartan—AGTR1—GPCR downstream signaling—C3—glaucoma	0.000109	0.00129	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—GSTT1—glaucoma	0.000109	0.00129	CbGpPWpGaD
Valsartan—ALB—Transmembrane transport of small molecules—SLC6A1—glaucoma	0.000103	0.00121	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—SMO—glaucoma	0.000102	0.00121	CbGpPWpGaD
Valsartan—ALB—Selenium Micronutrient Network—TNF—glaucoma	0.000101	0.0012	CbGpPWpGaD
Valsartan—AGTR1—Signaling by GPCR—C3—glaucoma	9.94e-05	0.00118	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—FN1—glaucoma	9.88e-05	0.00117	CbGpPWpGaD
Valsartan—ALB—Hemostasis—TGFB2—glaucoma	9.66e-05	0.00114	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—TXN—glaucoma	9.43e-05	0.00112	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—NTRK2—glaucoma	9.32e-05	0.0011	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	8.78e-05	0.00104	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—ABCA1—glaucoma	8.67e-05	0.00103	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—CYP1B1—glaucoma	8.67e-05	0.00103	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—APOE—glaucoma	8.6e-05	0.00102	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—CAV1—glaucoma	8.53e-05	0.00101	CbGpPWpGaD
Valsartan—ALB—Metabolism—CA1—glaucoma	8.36e-05	0.000989	CbGpPWpGaD
Valsartan—ALB—Metabolism—CTSA—glaucoma	8.1e-05	0.000957	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—NGFR—glaucoma	8e-05	0.000946	CbGpPWpGaD
Valsartan—ALB—Metabolism—CA2—glaucoma	7.65e-05	0.000904	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—NTRK1—glaucoma	7.6e-05	0.000899	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—ABCA1—glaucoma	7.47e-05	0.000884	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—CYP1B1—glaucoma	7.47e-05	0.000884	CbGpPWpGaD
Valsartan—ALB—Hemostasis—SOD1—glaucoma	7.32e-05	0.000865	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GSTT1—glaucoma	7.31e-05	0.000865	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CDKN2B—glaucoma	7e-05	0.000828	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—GSTM1—glaucoma	6.93e-05	0.00082	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CA1—glaucoma	6.84e-05	0.000809	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—EDN1—glaucoma	6.72e-05	0.000795	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CTSA—glaucoma	6.63e-05	0.000784	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CA2—glaucoma	6.26e-05	0.00074	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—NGF—glaucoma	6.18e-05	0.00073	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—MTHFR—glaucoma	6.13e-05	0.000724	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—glaucoma	6.12e-05	0.000723	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—ABCA1—glaucoma	6.12e-05	0.000723	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	5.9e-05	0.000697	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—C3—glaucoma	5.87e-05	0.000694	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CYP1B1—glaucoma	5.83e-05	0.000689	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—ABCA1—glaucoma	5.83e-05	0.000689	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—APOE—glaucoma	5.7e-05	0.000674	CbGpPWpGaD
Valsartan—ALB—Platelet activation, signaling and aggregation—VEGFA—glaucoma	5.65e-05	0.000669	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—CAV1—glaucoma	5.65e-05	0.000668	CbGpPWpGaD
Valsartan—ALB—Hemostasis—MMP1—glaucoma	5.58e-05	0.00066	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—APOE—glaucoma	5.47e-05	0.000646	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CAV1—glaucoma	5.42e-05	0.00064	CbGpPWpGaD
Valsartan—ALB—Metabolism—TXN—glaucoma	5.39e-05	0.000637	CbGpPWpGaD
Valsartan—ALB—Hemostasis—CAV1—glaucoma	5.35e-05	0.000633	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—FN1—glaucoma	5.15e-05	0.000609	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—BAD—glaucoma	5.09e-05	0.000602	CbGpPWpGaD
Valsartan—ALB—Hemostasis—FN1—glaucoma	5.09e-05	0.000602	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—APOE—glaucoma	4.92e-05	0.000581	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—CAV1—glaucoma	4.87e-05	0.000576	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—GSTM1—glaucoma	4.66e-05	0.000551	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—TXN—glaucoma	4.41e-05	0.000521	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—NOS3—glaucoma	4.27e-05	0.000505	CbGpPWpGaD
Valsartan—ALB—Metabolism—GSTT1—glaucoma	4.18e-05	0.000494	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—MTHFR—glaucoma	4.12e-05	0.000487	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—NOS3—glaucoma	4.09e-05	0.000484	CbGpPWpGaD
Valsartan—ALB—Hemostasis—NOS3—glaucoma	4.05e-05	0.000478	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—APOE—glaucoma	4.02e-05	0.000476	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—glaucoma	3.99e-05	0.000471	CbGpPWpGaD
Valsartan—SLCO1B3—Metabolism—PTGS2—glaucoma	3.91e-05	0.000462	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—APOE—glaucoma	3.83e-05	0.000453	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—CAV1—glaucoma	3.8e-05	0.000449	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—CDKN1B—glaucoma	3.55e-05	0.000419	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GSTT1—glaucoma	3.42e-05	0.000404	CbGpPWpGaD
Valsartan—ALB—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	3.37e-05	0.000398	CbGpPWpGaD
Valsartan—ALB—Metabolism—CYP1B1—glaucoma	3.33e-05	0.000394	CbGpPWpGaD
Valsartan—ALB—Metabolism—ABCA1—glaucoma	3.33e-05	0.000394	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—MMP9—glaucoma	3.29e-05	0.000388	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—VEGFA—glaucoma	2.95e-05	0.000349	CbGpPWpGaD
Valsartan—ALB—Hemostasis—VEGFA—glaucoma	2.91e-05	0.000345	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—NOS3—glaucoma	2.87e-05	0.000339	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	2.76e-05	0.000326	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CYP1B1—glaucoma	2.72e-05	0.000322	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—ABCA1—glaucoma	2.72e-05	0.000322	CbGpPWpGaD
Valsartan—ALB—Metabolism—GSTM1—glaucoma	2.66e-05	0.000315	CbGpPWpGaD
Valsartan—SLCO1B1—Metabolism—PTGS2—glaucoma	2.63e-05	0.00031	CbGpPWpGaD
Valsartan—ALB—Metabolism—MTHFR—glaucoma	2.35e-05	0.000278	CbGpPWpGaD
Valsartan—AGTR1—Signaling Pathways—TP53—glaucoma	2.23e-05	0.000264	CbGpPWpGaD
Valsartan—ALB—Hemostasis—TP53—glaucoma	2.2e-05	0.00026	CbGpPWpGaD
Valsartan—ALB—Metabolism—APOE—glaucoma	2.19e-05	0.000259	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—GSTM1—glaucoma	2.18e-05	0.000258	CbGpPWpGaD
Valsartan—ALB—Metabolism—CAV1—glaucoma	2.17e-05	0.000256	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—MTHFR—glaucoma	1.93e-05	0.000228	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—APOE—glaucoma	1.79e-05	0.000212	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—CAV1—glaucoma	1.78e-05	0.00021	CbGpPWpGaD
Valsartan—ALB—Metabolism—NOS3—glaucoma	1.64e-05	0.000194	CbGpPWpGaD
Valsartan—ALB—Metabolism—PTGS2—glaucoma	1.5e-05	0.000177	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—NOS3—glaucoma	1.34e-05	0.000159	CbGpPWpGaD
Valsartan—CYP2C9—Metabolism—PTGS2—glaucoma	1.23e-05	0.000145	CbGpPWpGaD
